CE Mark approval was initially sought. The company has provided guidance that FDA approval process could take 2 years, yet the technology is a clear differentiator for cardiologists from this U.S. based company that it received the request directly from NIH for biopsies. The company holds numerous patents with long tails remaining. The revenue potential for this company, with its distribution agreements with Siemens and Philips, is enormous. There is a reason that nobody wants to sell. The valuation is still way too low and U.S. investors are not permitted to buy.
CE Mark approval was initially sought. The company has provided...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.030(2.33%) |
Mkt cap ! $403.7M | |||
| Open | High | Low | Value | Volume |
| $1.34 | $1.34 | $1.26 | $263.0K | 206.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 16000 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 25000 | 1 |
View Market Depth
| Last trade - 15.59pm 25/07/2025 (20 minute delay) ? |
| IMR (ASX) Chart |